MILLENNIUM PARTNERS: Form 8.3 - Xeris Pharmaceuticals, Inc.
29 Junio 2021 - 9:15AM
UK Regulatory
TIDM0A8E
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) Millennium International Management LP
Company dealt in Xeris Pharmaceuticals, Inc.
Class of relevant security to which US98422L1070
the dealings being disclosed relate
(Note 2)
Date of dealing 28(th) June 2021
1. INTERESTS AND SHORT POSITIONS
1. Interests and short positions (following dealing) in the class of
relevant security dealt in (Note 3)
Long Short
Number (%) Number (%)
(1) Relevant securities 599,475 44,038
(0.903%) (0.066%)
(2) Derivatives (other than options) - -
(3) Options and agreements to purchase/sell - -
Total 599,475 44,038
(0.903%) (0.066%)
1. Interests and short positions in relevant securities of the company,
other than the class dealt in (Note 3)
Class of relevant security: Long Short
Number (%) Number (%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total
Ap20
1. DEALINGS (Note 4)
1. Purchases and sales
Price per unit (Note 5)
Purchase/sale Number of relevant securities (USD)
Purchase 600 4.48
Purchase 800 4.48
Purchase 121,243 4.48
Purchase 12,631 4.48
Purchase 1,529 4.48
Purchase 452,986 4.48
Purchase 241,251 4.48
Purchase 14,025 4.48
Sale 505,342 4.48
Sale 900 4.69
Sale 200 4.70
Sale 4,193 4.74
Sale 8,000 4.68
Sale 250 4.67
Sale 1,020 4.61
Sale 800 4.75
Sale 231 4.66
Sale 3,455 4.60
Sale 3,928 4.63
Sale 6,422 4.58
Sale 741 4.56
Sale 364 4.52
Sale 6,726 4.57
Sale 2,242 4.59
Sale 1,972 4.62
Sale 100 4.55
Sale 14,930 4.47
Sale 1,000 4.53
Sale 4,300 4.54
Sale 281 4.46
Sale 4,035 4.50
Purchase 329 4.48
Sale 555,115 4.48
Sale 400 4.73
Sale 125 4.64
Sale 3 4.70
Sale 924 4.68
Sale 300 4.67
Sale 619 4.61
Sale 4,384 4.60
Sale 26,922 4.58
Sale 2,558 4.56
Sale 7,929 4.52
Sale 2,340 4.57
Sale 3,637 4.59
Sale 200 4.62
Sale 2,658 4.55
Sale 900 4.49
Purchase 1,461 4.47
Sale 2,792 4.53
Sale 300 4.54
Sale 95 4.78
Purchase 60 4.46
Sale 2,216 4.46
Sale 7,800 4.51
Sale 300 4.44
Purchase 530 4.48
Sale 18,674 4.48
Purchase 1 4.71
Sale 290 4.71
Sale 21 4.55
Purchase 14,995 4.48
Purchase 15,008 4.48
Purchase 15,857 4.48
Purchase 177,013 4.48
Purchase 3,120 4.48
1. Derivatives transactions (other than options transactions)
Product name, Nature of Number of relevant Price per unit (GBP)
e.g. CFD transaction (Note securities (Note (Note 5)
6) 7)
1. Exercising
Product name, Number of securities Exercise price per unit (Note 5)
e.g. call option
1. Other dealings (including transactions in respect of new securities)
(Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable) (Note 5)
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person relating to the
voting rights of any relevant securities under any option referred
to on this form or relating to the voting rights or future
acquisition or disposal of any relevant securities to which any
derivative referred to on this form is referenced. If none, this
should be stated.
None.
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure 29(th) June 2021
Contact name Milos Naumovic
Telephone number +44 203 650 8203
If a connected EFM, name of offeree/offeror with which
connected
If a connected EFM, state nature of connection (Note 10)
View source version on businesswire.com:
https://www.businesswire.com/news/home/20210629005621/en/
CONTACT:
Millennium Partners, L.P.
SOURCE: Millennium Partners, L.P.
Copyright Business Wire 2021
(END) Dow Jones Newswires
June 29, 2021 10:15 ET (14:15 GMT)
Xeris Biopharma (LSE:0A8E)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Xeris Biopharma (LSE:0A8E)
Gráfica de Acción Histórica
De May 2023 a May 2024
